<DOC>
	<DOCNO>NCT00025454</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness R115777 treat patient advance solid tumor .</brief_summary>
	<brief_title>R115777 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose R115777 patient advance malignant solid tumor . - Assess toxicity drug patient . - Determine , preliminarily , efficacy drug patient . - Determine potential predictor response patient treated drug . OUTLINE : This multicenter , dose-escalation study . Patients receive oral R115777 twice daily week 1 3 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos R115777 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A minimum 20 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant tumor deem incurable refractory therapy Advanced , recurrent , metastatic disease Previously treat least 1 chemotherapy regimen Brain metastasis allow asymptomatic control ( e.g. , prior surgical resection radiotherapy/radiosurgery ) steroids anticonvulsant PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Absolute granulocyte count least 1,500/mm3 Platelet count least 75,000/mm3 Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN Renal : Creatinine clearance least 60 mL/min OR Creatinine great 1.6 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosourea ) Endocrine therapy : See Disease Characteristics No concurrent hormonal therapy Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No prior radiotherapy field contain measurable target lesion unless evidence progression new lesion present No concurrent radiotherapy measurable lesion Surgery : See Disease Characteristics At least 3 week since prior major surgery recover Other : At least 2 week since prior proton pump inhibitor ( e.g. , omeprazole ) Concurrent H2 blocker ( e.g. , cimetidine relate drug ) antacids allow interval least 2 hour H2 blocker/antacid intake R115777 dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>